bêta
IA Trial Radar
L'essai clinique NCT06257823 (ENIGMA) pour Accident vasculaire cérébral ischémique, Accident ischémique transitoire est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte

Vascular Cognitive Decline and Dementia (ENIGMA)

En recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT06257823 (ENIGMA) est un essai observationnel pour Accident vasculaire cérébral ischémique, Accident ischémique transitoire. Son statut actuel est : en recrutement. L'étude a débuté le 1 avril 2021 et vise à recruter 140 participants. Dirigé par Aarhus University Hospital, l'essai devrait être terminé d'ici le 1 juin 2025. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 14 février 2024.
Résumé succinct
The ENIGMA study is a single-centre prospective clinical observational study with the aim to investigate vascular contributions to cognitive decline and dementia. By studying MRI-defined capillary dysfunction and EV profiles, the ENIGMA study links novel imaging and basic research techniques to a clinical cohort of stroke patients. With this study we hope to enhance the understanding of the mechanisms behind post-stroke cognitive decline and dementia.
Description détaillée
Post-stroke cognitive impairment (PSCI) is common. However, the underlying pathophysiology remains largely unknown. Understanding how microvascular changes relate to PSCI and finding markers that can predict PSCI, could be a first step towards better screening and management.

Cerebral capillary dysfunction is characterized by limited oxygen extraction from the brain capillaries due to age- and risk factor-related capillary flow heterogeneity. Capillary dysfunction is a pathophysiological feature of cerebral small vessel disease (cSVD) and may play an important role in the vascular mechanisms underlying PSCI. Extracellular vesicles (EVs) carry molecules between cells. EV profiles may change during acute stroke, in the chronic stroke phase, and according to the level of cSVD, and EV profiles may therefore act as disease biomarkers.

The ENIGMA study aims to investigate capillary dysfunction and EV profiles as predictors of cognitive function one year after acute ischemic stroke (AIS) and transient ischemic attack (TIA). Consecutive patients with AIS and TIA are included and followed for one year with follow-up visits at three and 12 months. An MRI is performed at 24 hours and 12 months after admission. EV profiles will be characterised from blood samples drawn at 24 hours and three months after admission. Cognitive function is assessed three and 12 months after AIS and TIA using the Repeatable Battery for the Assessment of Neuropsychological Status and the Montreal Cognitive Assessment (MoCA).

The study has two main objectives: 1) to study associations between capillary dysfunction and PSCI and 2) to assess associations between EV profiles and PSCI.

Titre officiel

Exploring Vascular Contributions to Cognitive Decline and Dementia

Conditions
Accident vasculaire cérébral ischémiqueAccident ischémique transitoire
Publications
Articles scientifiques et travaux de recherche publiés sur cet essai clinique:
Autres identifiants de l'essai
  • ENIGMA
  • 1-10-72-253-20
Numéro NCT
Date de début (réel)
2021-04-01
Dernière mise à jour publiée
2024-02-14
Date de fin (estimée)
2025-06-01
Inscription (estimée)
140
Type d'essai
Observationnel
Statut
En recrutement
Mots clés
Dementia
Cognitive impairment
MRI
Extracellular vesicles
Stroke
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
N/A
AUCUNE INTERVENTION
No intervention
Critère principal d'évaluation
Critères d'évaluationDescription de critèresPériode
Post-stroke cognitive decline
Change in RBANS index score from three to 12 months follow-up
12 months
Post-stroke cognitive impairment
Total RBANS index score
12 months
Critère secondaire d'évaluation
Critères d'évaluationDescription de critèresPériode
Post-stroke cognitive decline
Change in MoCA score from three to 12 months follow-up
12 months
Post-stroke cognitive impairment
MoCA score at 12 months follow-up
12 months
Post-stroke depression
Measured on the major depression inventory
12 months
Physical activity
Measured on the Physical Activity Scale for the Elderley
12 months
Critères d'éligibilité

Âges éligibles
Adulte, Adulte âgé
Âge minimum
60 Years
Sexes éligibles
Tous
  • AIS or TIA with a clinically relevant diffusion restriction identified on MRI DWI-sequence on admission
  • Admittance within 24 hours from symptom onset
  • Age ≥ 60

  • Dependency in activities of daily living (mRS score > 2)
  • Known dementia, neurodegenerative disease, or other significant brain disease
  • Concomitant life-threatening disease
  • Contraindications to undergo MRI
  • Allergy or intolerance to MRI contrast agents
  • eGFR < 30
  • Unable to give written informed consent
  • Deemed unfit for follow-up
Aarhus University Hospital logoAarhus University Hospital
Partie responsable de l'essai
Janne Kaergard Mortensen, Investigateur principal, Associate Professor, MD, PhD, Aarhus University Hospital
Contact central de l'essai
Contact: Janne Kaergaard Mortensen, PhD, +4521156903, [email protected]
Contact: Sigrid Vestergaard, MD, +4521456903, [email protected]
1 Centres de l'essai dans 1 pays
Aarhus University Hospital, Aarhus, 8000, Denmark
Janne Kaergaard Mortensen, PhD, Contact, +4521156903, [email protected]
Sigrid Vestergaard, MD, Contact, +4521456903, [email protected]
En recrutement